The Board of Directors of Zydus Lifesciences Limited approved the unaudited financial results for the quarter and nine months ended December 31, 2025, at their meeting held on February 9, 2026. The meeting commenced at 11:10 a.m. and concluded at 1:15 p.m., with results reviewed by the Audit Committee and taken on record by the Board pursuant to Regulation 33 of SEBI Listing Regulations.

Board Meeting and Regulatory Compliance

The company fulfilled its regulatory obligations under Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The financial results were prepared in accordance with Indian Accounting Standards (Ind AS) and underwent limited review by statutory auditors Deloitte Haskins & Sells LLP. The results are available on the company's website at www.zyduslife.com and on stock exchange platforms.

Consolidated Financial Performance Q3FY26

The company demonstrated robust consolidated performance during Q3FY26. Total revenue from operations reached ₹68,645 million, representing significant 30.30% year-over-year growth from ₹52,691 million in Q3FY25. Net profit for the quarter stood at ₹10,421 million compared to ₹10,235 million in the corresponding quarter of the previous year, marking a 1.82% increase.

Nine Months Performance FY26

For the nine months ended December 31, 2025, consolidated revenue from operations reached ₹195,614 million compared to ₹167,136 million in the corresponding period of the previous year, marking growth of 17.04%. Net profit for the nine-month period stood at ₹37,675 million against ₹33,546 million in the previous year, representing a 12.30% increase.

Standalone Financial Results

The standalone operations showed revenue from operations of ₹22,836 million for Q3FY26 compared to ₹25,159 million in Q3FY25. Net profit for the quarter reached ₹2,965 million compared to ₹4,706 million in the corresponding quarter of the previous year. For the nine months period, standalone revenue stood at ₹77,431 million with net profit of ₹18,378 million.

Exceptional Items and New Labour Codes Impact

The quarter's results were affected by exceptional items totaling ₹849 million, primarily attributed to the one-time impact of New Labour Codes implementation. Effective November 21, 2025, the Government of India consolidated 29 existing labour legislations into four Labour Codes, resulting in increased gratuity and leave encashment liability mainly due to changes in the definition of "wages" for employees and contract labourers.

Trading Window and Corporate Information

The Trading Window under SEBI (Prohibition of Insider Trading) Regulations, 2015 shall remain closed till Wednesday, February 11, 2026, and shall reopen from Thursday, February 12, 2026, for Directors and Designated Persons. The company operates from its registered office at Zydus Corporate Park, Ahmedabad, with CIN L24230GJ1995PLC025878, trading on BSE under code 532321 and NSE under symbol ZYDUSLIFE.

Zydus Lifesciences Limited has formally announced the superannuation of a key senior management personnel, marking a significant leadership transition within the pharmaceutical company. The announcement pertains to Mr. Manoj Kumar Kamra, who served as Senior Vice President-Corporate Affairs, and represents part of the company's ongoing compliance with regulatory disclosure requirements.

Superannuation Details

The company disclosed that Mr. Manoj Kumar Kamra has superannuated from his position as Senior Vice President-Corporate Affairs, with the cessation taking effect from the closing working hours of January 31, 2026. The superannuation represents a natural conclusion to his tenure in the senior management role.

Regulatory Compliance

The announcement was made in strict adherence to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015. The disclosure also references SEBI circulars dated November 11, 2024, and December 31, 2024, ensuring full compliance with the latest regulatory guidelines for senior management changes.

The formal communication was filed with both major stock exchanges where the company's shares are listed:

• BSE Limited (Code: 532321)
• National Stock Exchange of India Limited (Code: Zyduslife)

Corporate Governance

The disclosure was officially signed and submitted by Dhaval N. Soni, Company Secretary and Compliance Officer (Membership No. FCS7063), on January 31, 2026. The digital signature timestamp shows 16:59:37 +05'30', demonstrating the company's commitment to timely regulatory reporting.

The announcement includes comprehensive annexure details as required under the listing regulations, providing transparency regarding the nature and timing of the senior management change. This structured approach reflects the company's adherence to corporate governance standards and regulatory compliance protocols.